Supha Pharmachem Ltd

As of September 30, 2025, Supha Pharmachem Ltd has 881.99M shares outstanding.

As of September 30, 2025, Supha Pharmachem Ltd maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,033.80, indicating moderate leverage, while an interest coverage ratio of 1.13 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2025, Supha Pharmachem Ltd posted a return on equity (ROE) of 15.87, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.60 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.64, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.22, useful for judging operating efficiency across full business cycles. The company generates approximately 752.71M in revenue per employee across its workforce of 7.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.81 indicates how many times Supha Pharmachem Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2025, Supha Pharmachem Ltd recorded 38.17M in income tax expense. That works out to an effective tax rate of 24.15, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 158.08M, leaving 119.91M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Supha Pharmachem Ltd's stock has gained approximately 289.47% over the past 52 weeks. The 50-day moving average sits at 0.27, while the 200-day moving average is 0.37.

Over the twelve months ended September 30, 2025, Supha Pharmachem Ltd generated 5.27B in revenue and converted that into 119.91M in net income, yielding earnings per share of 0.16. EBITDA reached 56.66M, while operating income came in at 56.46M.

As of September 30, 2025, Supha Pharmachem Ltd holds 13.16M in cash and equivalents against 10.88B in total debt, resulting in a net debt position of 10.87B. Total book value stands at 1.05B, with working capital of 993.31M providing operational flexibility.

Over the twelve months ended September 30, 2025, Supha Pharmachem Ltd posted a gross margin of 2.94, reflecting its pricing power and cost economics. The operating margin of 1.07 and net profit margin of 2.28 provide insight into operational efficiency.

Supha Pharmachem Ltd's most recent stock split took place on April 15, 2025.